UNSPSC 51413703: Buflomedil hydrochloride

This classification denotes a phosphodiesterase inhibitor with the molecular formula C17H25NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3J944AFS8S, chemically known as 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone but more generally known as buflomedil hydrochloride, which bears US NIH Compound Identifier 2467. European Medicines Agency schedules Buflomedil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00891MIG.

Most nations, for tariff and trade purposes, schedule buflomedil hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, BUFLOMEDIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC1CC(C(C(C1)OC)C(=O)CCCN2CCCC2)OC.CL.

UNSPSC 51413703 Buflomedil hydrochloride is a Commodity code under which state and local governments procure specific pharmaceutical products for emergency medical services, public health programs, and multistate cooperative purchasing networks. Recent solicitations show that state and local buyers are purchasing both individual advanced life support medications and participating in broader generic pharmaceutical supply contracts through established wholesaler networks and direct-to-manufacturer programs. The issuing bodies span municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances, with activity concentrated among large metros and state-level health procurement offices that aggregate demand across multiple jurisdictions.

The code sees recent activity in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue, requesting sealed bids with a firm price including freight and taxes, a one-year term with two one-year renewal options, and an estimated contract value of $40,000.00; the solicitation includes a 5 percent bid discount for Small Local Business Enterprise participation and requires Safety Data Sheets compliant with OSHA standards. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for Generic Multi Source Pharmaceuticals and OTC Products with a March 26, 2026 response deadline and July 1, 2026 contract effective date; vendors must maintain relationships with three authorized wholesalers and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, a preliminary market-intelligence phase to inform future formal procurement strategy.